A tumour-promoting protein, (SK1), was identified in prostate and breast cancer cells which reduces the effectiveness of chemotherapy.
Based on the above, a novel drug delivery system was designed using nanoparticles containing a combination of clinically approved SK1 inhibitor Fingolimod together with Taxane chemotherapy. This unique system targets cancer sites with greater accuracy – safely delivering powerful drugs and increasing the efficiency of the chemotherapy treatment.
UEA researchers believe the new drug delivery system, once fully developed, will result in more positive outcomes in prostate and breast cancer patients.
This EIRA-funded proof of concept project enabled the novel cancer treatment to move closer towards human phase 1 clinical trials.
Visit the EIRA website to read the full case study.
